GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. SPY
4. JPM
5. ICLR
6. USO
7. FUL
8. LAES

Go back to GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.89 +0.80 (1.57%)
Previous Close $51.09    52 Week High $45.58 
Open $51.96    52 Week Low $37.82 
Day High $52.48    P/E N/A 
Day Low $51.72    EPS $0.00 
Volume 3,644,370       

GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.89 +0.80 (1.57%)
Previous Close $51.09    52 Week High $45.58 
Open $51.96    52 Week Low $37.82 
Day High $52.48    P/E N/A 
Day Low $51.72    EPS $0.00 
Volume 3,644,370